Some studies have indicated that effective treatment of NSCLC cells with EGFR inhibitors is associated with suppression of PI3K activity and resistance to these inhibitors occurs with reactivation of the PI3K-Akt signaling pathway [32]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.